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ABSTRACT
Background
There are at least two phases of b-cell death during the development of autoimmune
diabetes: an initiation event that results in the release of b-cell-specific antigens, and a second,
antigen-driven event in which b-cell death is mediated by the actions of T lymphocytes. In this
report, the mechanisms by which the macrophage-derived cytokine interleukin (IL)-1 induces b-
cell death are examined. IL-1, known to inhibit glucose-induced insulin secretion by stimulating
inducible nitric oxide synthase expression and increased production of nitric oxide by b-cells,
also induces b-cell death.
Methods and Findings
To ascertain the mechanisms of cell death, the effects of IL-1 and known activators of
apoptosis on b-cell viability were examined. While IL-1 stimulates b-cell DNA damage, this
cytokine fails to activate caspase-3 or to induce phosphatidylserine (PS) externalization;
however, apoptosis inducers activate caspase-3 and the externalization of PS on b-cells. In
contrast, IL-1 stimulates the release of the immunological adjuvant high mobility group box 1
protein (HMGB1; a biochemical maker of necrosis) in a nitric oxide-dependent manner, while
apoptosis inducers fail to stimulate HMGB1 release. The release of HMGB1 by b-cells treated
with IL-1 is not sensitive to caspase-3 inhibition, while inhibition of this caspase attenuates b-
cell death in response to known inducers of apoptosis.
Conclusions
These findings indicate that IL-1 induces b-cell necrosis and support the hypothesis that
macrophage-derived cytokines may participate in the initial stages of diabetes development by
inducing b-cell death by a mechanism that promotes antigen release (necrosis) and islet
inflammation (HMGB1 release).
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Insulin-dependent diabetes is an autoimmune disease
characterized by selective destruction of insulin-producing
b-cells found in pancreatic islets of Langerhans [1]. The
development of diabetes is characterized initially by insulitis,
in which leukocytes migrate to and invade islets. This is
followed by overt diabetes, distinguished by insulin insufﬁ-
ciency due to the destruction of a majority of b-cells [2,3].
Cytokines produced by inﬂammatory leukocytes and resident
and inﬂammatory macrophages are believed to contribute to
the loss of b-cell function and viability during the develop-
ment of autoimmune diabetes [4,5]. Interleukin (IL)-1 was
identiﬁed as the active component of conditioned medium
derived from activated human mononuclear cells that causes
an inhibition of insulin secretion and the loss of islet cell
viability, provided the initial evidence supporting a role for
cytokines in the pathogenesis of autoimmune diabetes [6,7].
The mechanisms by which cytokines impair b-cell function
have been described in detail. Alone or in combination with
interferon (IFN)-c and tumor necrosis factor (TNF), IL-1 has
been shown to stimulate b-cell expression of inducible nitric
oxide synthase (iNOS), and the resulting production of nitric
oxide impairs b-cell oxidation of glucose to CO2, reduces the
activity of the Krebs cycle enzyme aconitase, and reduces islet
ATP levels by more than 4-fold [8,9]. Importantly, glucose-
induced insulin secretion is dependent on b-cell depolariza-
tion and Ca
2þ entry, events that are mediated by the
inhibition of ATP-sensitive K
þ channels due to the accumu-
lation of ATP that is produced by mitochondrial oxidation of
glucose to CO2 [10,11]. The targeted disruption of mitochon-
drial oxidation resulting in the reduction of cellular levels of
ATP is one mechanism by which nitric oxide impairs glucose-
stimulated insulin secretion. The damaging actions of
cytokines on b-cell function appear to be selective for b-
cells, as IL-1 fails to impair the ability of a-cells to oxidize
glucose to CO2 [12]. Furthermore, b-cells are the primary
islet-cell source of iNOS in response to cytokine treatment
[13,14]. The macrophage-derived cytokine IL-1 is the major
regulator of iNOS expression by b-cells, IL-1 alone is
sufﬁcient to stimulate iNOS expression by rat b-cells, and
combinations of IL-1 and IFN-c stimulate b-cell expression of
iNOS in most mouse strains and in human islets [4,9,15].
Biochemical and genetic evidence supports a primary role for
nitric oxide as the major mediator of cytokine-induced b-cell
damage. The NOS inhibitors N
G-monomethyl-L-arginine
(NMMA) and aminoguanidine (AG) prevent the inhibitory
actions of cytokines on insulin secretion, glucose oxidation,
and aconitase activity by rat, mouse, and human islets [4,8,9].
In addition, islets isolated from iNOS-deﬁcient mice are
resistant to the inhibitory actions of cytokines on insulin
secretion [16], and expression of iNOS under control of the
rat insulin promoter results in the development of diabetes in
a nitric oxide-dependent manner that occurs in the absence
of insulitis [17].
While autoimmune diabetes is characterized by selective
destruction of b-cells, the biochemical mechanisms by which
b-cells are killed are poorly deﬁned. In vitro studies using
isolated islets and primary b-cells have shown that nitric
oxide is a primary mediator of impaired b-cell function in
response to cytokine treatment; however, the role of this free
radical as a mediator of b-cell death and the mechanism of
cell death has been debated. Much of this debate has centered
on whether cytokine-induced islet cell death is apoptotic or
necrotic and if nitric oxide is a mediator [18–20]. Early
studies by Kolb and coworkers demonstrated that nitric oxide
is responsible for IL-1-stimulated DNA damage in b-cells [21].
More recently, cytokines have been reported to induce b-cell
apoptosis by a process that requires prolonged exposures of
7 9 d and that appears to occur by nitric oxide-independent
mechanisms [19,22]. Similar to the inhibitory actions of
cytokines on b-cell function, the macrophage-derived cyto-
kine IL-1 appears to be the primary regulator of cytokine-
induced b-cell death, be it by necrosis or apoptosis [18,19,23].
In classical terms, apoptosis is deﬁned as programmed cell
death by a pathway that removes unwanted cells in the
absence of an inﬂammatory response. It is a highly organized,
energy-dependent process that is characterized by caspase
activation, the ordered cellular degradation of proteins and
organelles, and maintenance of plasma membrane integrity.
The ﬁnal result is noninﬂammatory phagocytosis of the dying
cell, which minimizes leakage of cellular contents and
inﬂammation [24,25]. In contrast, necrosis is an inﬂammatory
process that is characterized by the loss of membrane
integrity and the leakage of cellular contents into the
extracellular space. It is an unregulated form of cell death
that does not require energy or caspase activation [26]. When
considering the role of macrophage-derived cytokines such as
IL-1 in the context of the initiation of autoimmune diabetes,
one would anticipate that this cytokine would kill b-cells by a
mechanism that would promote inﬂammation. In this report,
we compare the effects of IL-1 with known inducers of
apoptosis on b-cell death.
Methods
Materials and Animals
Sprague Dawley rats were purchased from Harlan (Indian-
apolis, Indiana, United States). RINm5F (rat insulinoma) cells
were obtained from Washington University Tissue Culture
Support Center (St. Louis, Missouri, United States). RPMI
1640 containing L-glutamine, CMRL-1066 tissue culture
medium, L-glutamine, penicillin, and streptomycin were
obtained from GIBCO-BRL (Grand Island, New York, United
States). FCS was obtained from Hyclone Laboratories (Logan,
Utah, United States). Human recombinant IL-1b was ob-
tained from Cistron Biotechnology (Pine Brook, New Jersey,
United States). Sodium (Z)-1(N,N-diethylamino) diazen-1-
ium-1,2-diolate (DEANO) was obtained from Alexis (San
Diego, California, United States). Enhanced chemilumines-
cence reagent was purchased from Amersham Pharmacia
Biotech (Piscataway, New Jersey, United States). MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), neu-
tral red, DAPI (49,6-diamidino-2-phenylindole dihydrochlor-
ide), camptothecin, and staurosporine were obtained from
Sigma (St. Louis, Missouri, United States). In Situ Cell Death
Detection kit was obtained from Roche (Indianapolis,
Indiana, United States). Caspase-3 Fluorometric Assay was
obtained from R&D Systems (Minneapolis, Minnesota, United
States). Annexin V-FITC Apoptosis Detection kit and the
caspase-3 inhibitor Z-DQMD-CHO were obtained from
Calbiochem (San Diego, California, United States). Guinea
pig anti-human insulin antibody was obtained from Linco
Research (St. Louis, Missouri, United States). CY3-conjugated
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key anti-rabbit and donkey anti-mouse antisera were ob-
tained from Jackson Immunoresearch Laboratories (West
Grove, Pennsylvania, United States). Rabbit anti-mouse
HMGB1 antibody was obtained from BD Biosciences Phar-
mingen (San Diego, California, United States). All other
reagents were from commercially available sources.
Islet Isolation and Cell Culture
Islets were isolated from 250- to 300-g male Sprague
Dawley rats by collagenase digestion as previously described
[27]. Islets were cultured overnight in complete CMRL-1066
(containing 2 mM L-glutamine, 10% heat-inactivated fetal
calf serum, 100 U/ml penicillin, 100 lg/ml streptomycin, and
5.5 mM glucose) at 37 8C under an atmosphere of 95% air and
5% CO2 prior to experimentation. For annexin V and
terminal nick-end labeling (TUNEL) assays of cell death, rat
islets were treated with IL-1 for the indicated times followed
by dispersion into individual cells by trypsin digestion as
previously described [27]. RINm5F cells were grown in RPMI
1640 tissue culture medium to a density of ;75% prior to
experimentation. The cells were then removed from growth
ﬂasks by treatment with 0.05% trypsin and 0.02% EDTA for 5
min at 37 8C, washed two times with complete CMRL-1066
media, and plated in CMRL-1066 at the indicated density.
Human islets were obtained from the Islet Cell Resource
Center at Washington University School of Medicine (St.
Louis, Missouri, United States). Before experiments, the
human islets were cultured for 48 h at 37 8C in complete
CMRL-1066 tissue culture medium in an atmosphere of 95%
air and 5% CO2.
Cell Death Assays
Cell viability was examined using the MTT assay and
neutral red uptake. The MTT assay is based on the ability of
viable cells to reduce MTT to insoluble formazan crystals [28].
For this assay, RINm5F cells or rat islet cells (1 3 10
5 cells in
200 ll of complete CMRL-1066) were washed with tissue
culture medium following treatments, and MTT was added at
a ﬁnal concentration of 0.5 mg/ml. Following an incubation
for 3 h at 37 8C, the supernatants were removed and
discarded, and the cells were lysed with acid-isopropanol
(100 ll of 0.04 N HCl in isopropanol) and mixed thoroughly
to dissolve the crystals for 5 min at room temperature. The
optical density of this product was determined at a wave-
length of 570 nm.
Cell viability was also evaluated by examining the accumu-
lation of neutral red dye in viable cells [29]. For this assay,
RINm5F cells or dispersed rat islet cells (1310
5 cells in 200 ll
of complete CMRL-1066) were cultured for 24 or 48 h with
the indicated concentrations of IL-1, camptothecin, or
staurosporine; the culture supernatants were removed and
discarded; and the cells were incubated in fresh medium
containing 50 lg/ml neutral red at 37 8C. Following a 2-h
incubation, the supernatant was removed, the cells were
washed with a 1% formaldehyde-1% CaCl2 solution, and the
neutral red dye was extracted in 100 ll of a 50% ethanol-1%
acetic acid lysing solution. The accumulation of neutral red
dye in the lysing solution was measured at a wavelength of 570
nm. Cell viability using both the MTT and neutral red assays
is expressed as the percent of dead cells.
Annexin V-FITC Staining
RINm5F cells or rat islet cells (1 3 10
5 cells in 200 llo f
complete CMRL-1066) were treated as indicated in the ﬁgure
legends. Cells were removed from plates by cell scraping
(RINm5F) or washing (islet cells). Externalization of phos-
phatidylserine (PS) was evaluated by annexin V staining
according to manufacturer’s instructions (Calbiochem) and
quantiﬁed by ﬂow cytometry [30].
TUNEL Staining/Immunohistochemistry
RINm5F cells or rat islet cells (4 3 10
5 cells in 400 llo f
complete CMRL-1066) were treated as indicated in the ﬁgure
legends. The cells were removed from plates and centrifuged
onto glass slides. DNA damage was quantiﬁed by TUNEL
staining according to the manufacturer’s instructions using
the In Situ Cell Death Detection Kit, Fluorescein (Roche).
Cells containing DNA damage were colocalized with DAPI by
incubating cells with DAPI (5 lg/ml) for 15 min followed by
three washes with PBS (pH 7.4). DNA damage in rat islet cells
was colocalized with insulin-containing cells as outlined
previously [31].
Caspase-3 Activity
RINm5F cells or rat islet cells (4 3 10
5 cells in 400 llo f
complete CMRL-1066) were treated as indicated in the ﬁgure
legends. Cells were isolated and lysed, and capase-3 activity in
the cell lysate was determined according to the manufac-
turer’s instructions (Caspase-3 Fluorometric Assay Kit, R&D
Systems). Caspase-3 activity was normalized to protein
content and is presented as the fold-increase over the level
of activity measured in the untreated control.
Western Blot Analysis
Protein lysates prepared from RINm5F cells and rat islets
were separated by SDS-PAGE and then transferred to
nitrocellulose membranes (Amersham Pharmacia Biotech)
under semidry transfer conditions as previously described
[32]. Antigen was detected by enhanced chemiluminescence
according to the manufacturer’s speciﬁcations (Amersham
Pharmacia Biotech). Antibody dilutions were: rabbit anti-
mouse HMGB1, 1:1,000; and HRP-conjugated donkey anti-
rabbit, 1:7,000.
Nitrite Determination
Nitrite production was determined by mixing 50 ll of cell
culture medium with 50 ll of Griess reagent [33]. The
absorbance at 540 nm was measured, and nitrite concen-
trations were calculated from a sodium nitrite standard
curve.
Statistics
Statistical comparisons were made between groups using
one-way ANOVA. Signiﬁcant differences between groups (p
, 0.05) were determined by Newman-Keuls post-hoc analysis.
Results
Nitric Oxide Mediates Cytokine-Induced Islet Cell Death
While it is clear that the inhibitory actions of cytokines
such as IL-1 on glucose-stimulated insulin secretion are
mediated by b-cell production of nitric oxide, the role of
nitric oxide in islet cell death has been debated [8,18,19].
Short exposures (24–48 h) of islets and insulinoma cell lines
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islet cell DNA damage and reduced oxidative capacity in a
nitric oxide-dependent fashion [34–36]; however, prolonged
exposures (7–9 d) of islets or puriﬁed b-cells with IL-1 or
cytokine combinations have been reported to induce b-cell
apoptosis in a nitric oxide-independent manner [19,22]. To
investigate the mechanisms of cytokine-induced b-cell death,
we initially examined whether IL-1 reduces b-cell viability
using the MTT assay. Following a 24-h incubation with IL-1,
death of RINm5F cells increased ;20% (Figure 1A), and this
cell death correlated with a ;10-fold increase in production
of nitrite, an oxidative metabolite of nitric oxide (Figure 1B).
Following a 48-h incubation with IL-1, RINm5F cell death
increased to ;40% (Figure 1A), and cell death correlated
with a ;20-fold increase in nitrite production (Figure 1B).
The NOS inhibitor NMMA prevented nitrite production
(Figure 1B) and signiﬁcantly attenuated IL-1-induced
RINm5F cell death (Figure 1A). Similar to its effect in
RINm5F cells, IL-1 induced the death of ;25% of islet cells
following 24- and 48-h incubations (Figure 1C). IL-1-induced
islet cell death correlated with an increase in nitric oxide
production (Figure 1D), and NMMA attenuated both islet cell
death and nitric oxide production. These ﬁndings suggest
that IL-1 induces islet and RINm5F cell death, that cell death
correlates with the production of nitric oxide, and that cell
death is attenuated by the inhibition of NOS.
Figure 1. Nitric Oxide Mediates IL-1-Induced b-Cell Death as Determined by the MTT Assay
RINm5F cells (A and B) or rat islets (C and D) were treated with IL-1 (10 units/ml) and NMMA (2 mM) for either 24 or 48 h, as indicated. The cells were
isolated and viability determined using the MTT assay (A and C). The culture supernatants were isolated and nitrite production was determined using
the Griess assay (B and D).
(E and F) The effects of exogenously produced nitric oxide supplied by the donor compound DEANO (500 lM) and the apoptosis inducer camptothecin
(25 lM) on RINm5F cell viability (E) and the apoptosis inducer staurosporine on rat islet cell viability (F) were determined by MTT assay.
Cell viability data is expressed as percent death. Results for cell viability and nitrite production are the average 6 standard error of the mean (SEM) of
three independent experiments. *p , 0.05, significantly different from untreated controls. **p , 0.05, significantly different from IL-1-treated condition.
DOI: 10.1371/journal.pmed.0030017.g001
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viability, the effects of exogenously supplied nitric oxide on
RINm5F cell viability were examined. RINm5F cells were
chosen for these studies because they represent a homoge-
nous population of b-cells, and the effects of cytokines on
these cells have been characterized in detail [9]. Treatment of
RINm5F cells for 24 h with the nitric oxide donor compound
DEANO resulted in a 25% increase in cell death (Figure 1E).
Following a 48-h exposure to DEANO, the level of death was
not further increased, a ﬁnding that is likely due to the rapid
decomposition of DEANO (which has a half-life of ;2 min
under these conditions). The effects of DEANO were
compared to known inducers of apoptosis. The topoisomer-
ase inhibitor camptothecin is a classical inducer of apoptosis
in rapidly proliferating cell lines [37] and, as shown in Figure
1E, induces the death of ;40% and 75% of RINm5F cells
following 24- and 48-h incubations, respectively. Camptothe-
cin is not an effective inducer of islet cell death (most likely
due to the quiescent nature of these cells [unpublished data]);
however, the kinase inhibitor staurosporine, another known
inducer of apoptosis [38], stimulated the death of ;40% of
islet cells following a 24-h incubation (Figure 1F).
A second assay of cell viability, neutral red uptake, was used
to conﬁrm the observations that cytokines induce b-cell death
(Figure 2). This assay is based on the ability of viable cells to
accumulate neutral red dye, while nonviable cells fail to
accumulate this dye [29]. Similar to the results presented for
the MTT assay in Figure 1, IL-1 reduced RINm5F cell viability
by ;20%–25% following 24- or 48-h incubations, and cell
death in response to this cytokine was attenuated by NMMA
(Figure 2A). The apoptosis inducer camptothecin also
reduced RINm5F cell viability by ;60%–80% following 24-
and 48-h incubations, as determined by neutral red uptake
(Figure 2B). These ﬁndings provide evidence, in two different
assays of cell death, that IL-1 reduces b-cell viability and that
the loss of viability is mediated, in part, by the production of
nitric oxide.
Morphological Analysis of IL-1-Induced b-Cell Death
While performing the cell viability experiments, clear
morphological differences were observed for RINm5F cells
treated with IL-1 as compared to the apoptosis inducer
camptothecin. Control, untreated RINm5F cells grew as a ﬂat
monolayer of cells with distinct cell borders (Figure 3A).
Treatment with IL-1 resulted in morphological changes that
included cell swelling and the appearance of holes in the
cytoplasm (Figure 3B), changes that are consistent with a
necrotic form of cell death. Nitric oxide appears to be
responsible for the morphological changes induced by IL-1,
as NMMA attenuated RINm5F cell swelling and the formation
of cytoplasmic holes (Figure 3C). The morphological changes
in RINm5F cells undergoing apoptosis were strikingly differ-
ent from the alterations induced by IL-1. RINm5F cells that
underwent apoptosis following a 24-h treatment with
camptothecin were severely shrunken and contained com-
pacted nuclei, consistent with an apoptotic morphology
(Figure 3D). This morphological analysis of the effects of IL-
1 on RINm5F cell viability suggests that cytokine-induced b-
cell death is not caused by classical apoptotic mechanisms
and may occur by necrotic mechanisms.
IL-1 Stimulates b-cell DNA Damage in a Nitric Oxide-
Dependent Manner
The TUNEL assay is commonly used to detect DNA damage
in cells, and the results have frequently been used as evidence
to support an apoptotic pathway of cell death. Using the
TUNEL assay, the effects of IL-1 on the integrity of RINm5F
and rat islet cell DNA were examined. In this assay, DNA
strand breaks were detected by the incorporation of
ﬂuorescein dUTP (green ﬂuorescence, Figure 4), and nuclei
were visualized by co-staining with DAPI (blue ﬂuorescence,
Figure 4) or colocalized with insulin-containing islet cells
(using a CY3-conjugated secondary antibody; red ﬂuores-
cence, Figure 5). Treatment of RINm5F cells for 24 h with IL-
1 resulted in DNA damage in ;50% of the cells (see Figure
4B), and the level of DNA damage increased to ;65% of the
cells following a 48-h incubation (see Figure 4C). Importantly,
IL-1-induced DNA damage was attenuated by NMMA to levels
similar to those observed in untreated control cells (;5%–
8% TUNEL-positive; see Figure 4E and 4F). Representative
ﬂuorescent micrographs indicate that the morphology of
TUNEL-positive RINm5F cells following treatment with IL-1
is signiﬁcantly different from the morphology of cells treated
with the apoptosis inducer camptothecin. While TUNEL
staining in most RINm5F cells treated with IL-1 appeared
uniform throughout the nuclei and colocalized with DAPI
staining, there were a number of RINm5F cells in which the
TUNEL staining appears to spill out of the nucleus (see Fig-
ure 4B and 4C, white arrows), indicating a loss of nuclear
membrane integrity. Camptothecin stimulated DNA damage
Figure 2. Effects of IL-1 on b-Cell Viability as Determined by Neutral Red
Uptake
RINm5F cells were treated for 24 h or 48 h with IL-1 (10 units/ml), NMMA
(2 mM) (A), or camptothecin (25 lM) (B), and the cells were isolated and
percentage of death determined using the neutral red uptake assay.
Results are average 6 SEM of three independent experiments. *p , 0.05,
significantly different from untreated controls. **p , 0.05, significantly
different from IL-1-treated condition.
DOI: 10.1371/journal.pmed.0030017.g002
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arrow), and the pattern of TUNEL and DAPI staining was
distinctly different from that observed following IL-1 treat-
ment. Camptothecin-induced TUNEL and DAPI staining
appears more intense and punctate, indicating that chroma-
tin condensation has occurred.
Similar to RINm5F cells, treatment of rat islets for 48 h
with IL-1 resulted in DNA damage in ;50% of islet cells, and
over 95% of this DNA damage was found in b-cells, as
determined by immunolocalization of TUNEL-positive cells
with insulin-containing cells (Figure 5B). IL-1-induced DNA
damage was prevented by NMMA (Figure 5D), indicating that
nitric oxide is primarily responsible for the DNA damage
observed in rat islet cells treated with IL-1. IL-1-induced DNA
damage was compared with damage caused by the apoptosis
inducer staurosporine. Treatment of rat islets for 48 h with
staurosporine resulted in TUNEL-positive staining in ;50%
of islet cells, and this DNA damage was observed in both
insulin-containing and non-insulin-containing cells (Figure
5C). Similar to RINm5F cells (see Figure 4), the morphology
of TUNEL staining in the IL-1-treated islet cells appears
uniform throughout the nucleus (Figure 5B, white arrows). In
contrast, staurosporine-induced TUNEL staining in islet cells
was more intense and punctate (Figure 5C, white arrows).
Taken together, these ﬁndings suggest that IL-1 stimulates
DNA damage in b-cells, and that nitric oxide is a primary
mediator of this damage. In addition, these ﬁndings indicate
that DNA damage induced by IL-1 results in morphological
changes in b-cells that are markedly different from the DNA
damage observed in b-cells undergoing staurosporine-in-
duced apoptosis.
IL-1 Fails to Activate Caspase-3 in RINm5F Cells or Rat Islets
To directly examine whether IL-1 induces classical apop-
tosis in rat islets or RINm5F cells, the effects of this cytokine
on the activation of caspase-3 were examined. We decided to
Figure 3. Morphological Analysis of IL-1-Induced RINm5F Cell Death
RINm5F cells were treated for 24 h with IL-1 (10 units/ml) (B and C), NMMA (2 mM) (C), or camptothecin (25 lM) (D), and cellular morphology was
examined by phase-contrast microscopy. Treatment with IL-1 resulted in cell swelling and detachment (B), events that are prevented by NMMA (C). In
contrast to the effects of IL-1, induction of apoptosis using camptothecin (D) resulted in cell shrinkage and condensation of the nucleus. Untreated
control cells are shown in (A). Results are representative of three independent experiments.
DOI: 10.1371/journal.pmed.0030017.g003
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a downstream target of caspases involved in both the intrinsic
and extrinsic pathways of apoptosis [39,40]. IL-1 failed to
stimulate caspase-3 activation in RINm5F cells (Figure 6A) or
rat islets (Figure 6B) treated for either 24 or 48 h. Since nitric
oxide is a known inhibitor of caspase activity [41–43], the
effects of IL-1 alone and in combination with NMMA on
caspase-3 activity were examined. In the presence of NMMA,
IL-1 still failed to stimulate caspase-3 activation in RINm5F
cells or rat islets. In contrast to the lack of caspase-3
activation in response to IL-1, camptothecin induced a ;9-
fold increase in caspase-3 activity in RINm5F cells (Figure
6A), and staurosporine stimulated a ;5-fold increase in
caspase-3 activity in rat islets (Figure 6B).
Effects of IL-1 on Annexin V Staining in RINm5F Cells and
Rat Islets
The externalization of PS on the outer membrane surface
of cells is a hallmark of cells undergoing early or intermediate
stages of apoptosis that can be quantiﬁed by ﬂow cytometry
using the calcium-dependent phospholipid-binding protein
annexin V [30]. Using this assay, we show that IL-1 fails to
stimulate PS externalization on RINm5F cells (Figure 7A) or
rat islet cells (Figure 7B). In contrast, ;55% of RINm5F cells
stained positive for annexin V following a 24 or 48-h
incubation with camptothecin, and ;15% of rat islet cells
stained positive for annexin V following a 24- or 48-h
incubation with staurosporine. The absence of annexin V
staining on rat islet cells and RINm5F cells treated with IL-1 is
consistent with the lack of caspase-3 activation, and suggests
that, while IL-1 stimulates b-cell death, it does not appear to
occur by classical apoptotic mechanisms.
Biochemical Evidence that IL-1 Stimulates b-Cell Necrosis
HMGB1 is a chromatin-binding protein that is selectively
released by cells undergoing necrosis [26,44–46]. It is not
released from cells undergoing apoptosis, as it is sequestered
by chromatin [45]. To determine whether IL-1 stimulates b-
cell necrosis, RINm5F cells were treated for 24 or 48 h in the
presence or absence of NMMA, and the supernatants were
isolated and examined by Western blot analysis for the
presence of HMGB1. As shown in Figure 8A, IL-1 stimulates
the release of low levels of HMGB1 by RINm5F cells, which is
ﬁrst apparent following a 24-h incubation, with higher levels
Figure 4. IL-1 Stimulates RINm5F Cell DNA Damage in a Nitric Oxide-Dependent Manner
Treatment of RINm5F cells for 24 h (B) or 48 h (C) with IL-1 (10 units/ml) resulted in DNA damage, as determined by TUNEL staining (green fluorescence).
DNA damage was attenuated by NMMA (E and F). The apoptosis inducer camptothecin (25 lM) stimulated DNA damage (D), and this DNA damage is
morphologically distinct from that induced by IL-1. Nuclei are stained with DAPI (blue). The morphological differences in TUNEL staining, the loss of
nuclear membrane integrity in response to IL-1 (B and C) and the condensation of DNA in response to camptothecin (D) are highlighted using white
arrows. The levels of DNA damage in control cells (A) were less than 5%. Results are representative of three independent experiments.
DOI: 10.1371/journal.pmed.0030017.g004
Figure 5. IL-1 Stimulates Islet Cell DNA Damage in a Nitric Oxide-
Dependent Manner
Treatment of rat islet cells for 24 h with IL-1 resulted in DNA damage as
determined by TUNEL staining, and ;95% of this damage occurred in
insulin-containing cells (red fluorescence) (B). Nitric oxide appears to
mediate IL-1-induced DNA damage, as it was attenuated by the NOS
inhibitor NMMA (2 mM) (D). The apoptosis inducer staurosporine (1 lM)
also stimulated DNA damage in both insulin containing and non-insulin
containing cells (C). Less than 10% of control, untreated islet cells were
TUNEL-positive (A). Results are representative of three independent
experiments.
DOI: 10.1371/journal.pmed.0030017.g005
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b-Cell Necrosis and HMGB1 Releasereleased following a 48-h incubation. In a similar manner, IL-
1 stimulated the release of HMGB1 by rat islets (Figure 8B).
NMMA attenuates IL-1-induced HMGB1 release by both rat
islets and RINm5F cells, indicating that nitric oxide is a
mediator of b-cell necrosis. To conﬁrm that nitric oxide
induces b-cell necrosis, we show that a 24-h incubation of
RINm5F cells (Figure 8C) or rat islets (Figure 8D) with the
nitric oxide donor DEANO results in HMGB1 release. In
contrast, barely detectable levels of HMGB1 were released by
RINm5F cells treated with camptothecin or islets incubated
with staurosporine for 24 h (Figures 8C and 8D). As a control,
inactivated DEANO failed to stimulate HMGB1 release by
either rat islets or RINm5F cells (unpublished data). The
release of HMGB1 by rat islets and RINm5F cells provides
biochemical evidence that IL-1 stimulates b-cell death by
necrotic mechanisms.
Effect of Caspase-3 Inhibition on Cytokine-Induced b-Cell
Death
To further explore the mechanisms of b-cell death, the
effects of caspase-3 inhibition on b-cell death in response to
apoptosis inducers and IL-1 were examined. As expected, the
caspase-3 inhibitor Z-DQMD-CHO attenuated camptothecin-
induced RINm5F cell death, as determined by MTT assay
(Figure 9A), annexin V staining (Figure 9B), and caspase-3
activation (unpublished data). In contrast, inhibition of
caspase-3 failed to attenuate IL-1-induced RINm5F cell death
following a 24- or 48-h incubation (Figure 9C). Furthermore,
caspase-3 inhibition failed to prevent RINm5F cell HMGB1
release induced by the exogenous addition of nitric oxide by
the donor DEANO (Figure 9D), or following a 48-h
incubation with IL-1 (Figure 9E). These ﬁndings demonstrate
that b-cell death in response to IL-1 treatment does not
require the activation of caspase-3, an executioner caspase,
and that caspase-3 inhibition does not prevent b-cell necrosis
in response to IL-1 treatment or exposure to exogenous
nitric oxide, as assessed by the release of HMGB1.
Cytokines Stimulate HMGB1 Release from Human Islets in
a Nitric Oxide-Dependent Manner
In contrast to the effects of IL-1 on rat islets, a combination
of cytokines (IL-1, TNF, and IFN-c) is required to stimulate
Figure 6. IL-1 Fails to Activate Caspase-3 in RINm5F Cells or Rat Islets
(A) IL-1 (10 units/ml), alone or in combination with NMMA (2 mM) and
the nitric oxide donor DEANO (500 lM), failed to activate caspase-3 in
RINm5F cells following a 24- or 48-h exposure. As a positive control, the
apoptosis inducer camptothecin (25 lM) stimulated a 9-fold increase in
RINm5F cell caspase-3 activity.
(B) Similar to RINm5F cells, in rat islets IL-1 (10 units/ml) alone or in
combination with NMMA (2 mM) failed to activate caspase-3 following
a 24- or 48-h incubation. The apoptosis inducer staurosporine (1 lM)
stimulated a 5-fold increase in rat islet caspase-3 activity. Results are
the average 6 SEM of three independent experiments. *p , 0.05,
significantly different from untreated control.
DOI: 10.1371/journal.pmed.0030017.g006
Figure 7. Effects of IL-1 on Annexin V Staining in RINm5F Cells and Rat Islets
Treatment of RINm5F cells (A) or rat islet cells (B) with 10 units/ml IL-1 did not stimulate PS externalization, as determined by annexin V staining and
quantified by flow cytometry. In contrast, treatment of RINm5F Cells with camptothecin (25 lM) (A) or rat islet cells with staurosporine (1 lM) (B)
stimulated the externalization of PS. Results are presented as percent increase in annexin V-positive cells above the basal levels (;3%–7%) detected on
untreated control RINm5F or rat islet cells and are the average 6 SEM of three independent experiments. *p , 0.05, significantly different from
untreated control.
DOI: 10.1371/journal.pmed.0030017.g007
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b-Cell Necrosis and HMGB1 ReleaseFigure 8. IL-1 Stimulates HMGB1 Release in RINm5F Cells and Rat Islets
(A and B) RINm5F cells (A) or rat islets (B) were treated for 24 or 48 h with 10 units/ml of IL-1 and 2 mM NMMA as indicated. The levels of HMGB1
released into the supernatant (s) and contained in the cells (p) were determined by Western blot analysis. Results show that IL-1 stimulates the release
of HMGB1 from RINm5F cells and rat islets, and that this release is attenuated by the NOS inhibitor NMMA.
(C) Treatment of RINm5F cells for 24 h with DEANO (500 lM) stimulated HMGB1 release, while the apoptosis inducer camptothecin (25 lM) failed to
stimulate HMGB1 release from RINm5F cells.
(D) Nitric oxide supplied exogenously via treatment with DEANO (500 lM) also stimulated HMGB1 release by rat islets, while HMGB1 was not released
under conditions of b-cell apoptosis in response to treatment with staurosporine. Results are representative of three independent experiments.
DOI: 10.1371/journal.pmed.0030017.g008
Figure 9. Caspase-3 Inhibition Prevents b-Cell Apoptosis but Does Not Prevent IL-1-Induced Necrosis
The caspase-3 inhibitor Z-DQMD-CHO (100 lM) attenuated RINm5F cell death induced by a 24-h incubation with camptothecin as determined by MTT
assay (A) or annexin V staining (B). This caspase-3 inhibitor failed to prevent RINm5F cell death in response to a 48-h incubation with 10 units/ml IL-1 as
determined by the MTT assay (C). Z-DQMD-CHO also did not attenuate HMGB1 release by RINm5F cells treated for 24 h with 500 lM DEANO (D) or for
48 h with 10 units/ml IL-1 (E). The levels of HMGB1 released into the supernatant (s) and contained in the cells (p) were determined by Western blot
analysis. Results for MTT assay (A and B) and annexin V staining (C) are the average 6 SEM of three independent experiments. *p , 0.05, significantly
different from untreated control. **p , 0.05, significantly different from camptothecin-treated condition. Results for HMGB1 release are representative
of three independent experiments.
DOI: 10.1371/journal.pmed.0030017.g009
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b-Cell Necrosis and HMGB1 Releasenitric oxide synthase expression and nitric oxide production
from human islets. Previous studies have shown that,
individually, these cytokines fail to stimulate iNOS expression
or nitric oxide production, or to induce human islet cell
death [47–49]. To examine whether nitric oxide modulates
human islet viability, we examined the effects of a 48-h
incubation of human islets with IL-1, IFN-c, and TNF on the
release of HMGB1. Treatment of human islets with this
cytokine mixture stimulated a
~
7 fold increase in nitrite
production (Figure 10A), and nitric oxide production
correlated with high levels of iNOS expression (unpublished
observation). Importantly, under conditions in which human
islets produce nitric oxide, HMGB1 accumulated in the
supernatant of these islet cultures (Figure 10B). HMGB1
release appears to be dependent on the production of nitric
oxide, as the iNOS selective inhibitor AG attenuated the
production of nitric oxide and the release of HMGB1 by
human islets. The apoptosis inducer staurosporine failed to
stimulate the production of nitric oxide or release of
HMGB1. Alone, neither IL-1, TNF, nor IFN-c stimulated
nitric oxide production, iNOS expression, or the release of
HMGB1 from human islets following a 24- or 48-h incubation
(unpublished data), providing evidence that the increased
production of nitric oxide by human islets in response to the
combination of cytokines is required for the release of
HMGB1 by human islets. Overall, these ﬁndings are consis-
tent with the effects of IL-1 on rat islets and RINm5F cells, in
that they provide direct evidence that nitric oxide mediates
the release of HMGB1, a marker of necrotic cell death, by
human islets in response to cytokine treatment.
Discussion
Autoimmune diabetes is characterized by an inability to
regulate blood glucose levels due to the autoimmune
destruction of insulin-producing pancreatic b-cells. The
development of autoimmune diabetes is a T cell-dependent
process, as they represent a major cellular constituent found
in insulitis, and it is possible to prevent diabetes by T cell
depletion [2,3,50]. While T cells are responsible for killing the
majority of b-cells during the development of diabetes,
relatively little is known concerning the events that initiate
this autoimmune response directed against b-cells. Mathis
and coworkers [3,51] have recently proposed that b-cell death
during normal physiological islet remodeling, which peaks at
14–17 d after birth, may supply b-cell antigens that can then
be engulfed by dendritic cells. These antigen-presenting cells
(APCs) then ferry the antigen to pancreatic lymph nodes,
where they may activate naı ¨ve diabetogenic T cells [3,51].
Although the mechanisms of b-cell death during islet
Figure 10. Nitric Oxide-Dependent Release of HMGB1 from Cytokine-Treated Human Islets
Human islets (200 islets in 400 ll of complete CMRL-1066) were treated with a combination of IL-1 (50 units/ml), IFN-c (500 units/ml), and TNF (50 nM) in
the presence or absence of the NOS inhibitor AG (2 mM) or treated with staurosporine (1 lM) alone.
(A) Following 48h -incubation the supernatant was removed and nitrite production was determined using the Griess assay. The levels of HMGB1
released into the supernatant (s) and contained in the islets (p) were determined by Western blot analysis.
(B) Results indicate that cytokine-stimulated HMGB1 release correlates with nitric oxide production, and that inhibition of nitric oxide production using
AG attenuates HMGB1 release from human islets. Similar results have been obtained in three of five independent preparations of human islets.
DOI: 10.1371/journal.pmed.0030017.g010
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b-Cell Necrosis and HMGB1 Releaseremodeling are likely apoptotic, it is possible to mount a T
cell response by antigens produced by cells undergoing
apoptotic cell death [52].
While experimental evidence supports this model for
initiation of diabetes in the NOD mouse [51], this model
does not take into account the low concordance rate and
variable time of onset of diabetes observed in identical twins
[53,54]. Speciﬁcally, if b-cell death during normal physiolog-
ical islet remodeling supplies antigens that activate naı ¨ve
diabetogenic T cells, one would have to assume that the
extent/efﬁciency of b-cell death and/or antigen processing
and presentation to naı ¨ve T cells may be highly variable in
individuals with an identical genetic makeup. An alternative
hypothesis to explain the initiation of autoimmune diabetes,
proposed by Lacy [55,56], suggests that intraislet macrophage
activation and local release of macrophage-derived inﬂam-
matory mediators initiates b-cell death, antigen release, and
autoimmunity directed against b-cells. The initiating event
leading to intraislet macrophage activation may be viral,
bacterial, or chemical in origin. It is well known that viral or
bacterial infection stimulates macrophage production of IL-1
and TNF, and these cytokines have been shown to impair b-
cell function and induce b-cell death [4,5,57]. In support of
this model, previous studies have shown that feeding rodents
a diet deﬁcient in essential free fatty acids, known to deplete
resident macrophages [58,59], attenuates diabetes induced by
the chemical toxin streptozotocin [60] and the natural
progression of diabetes in BB rats [61]. In addition, a number
of studies have shown that the local release of IL-1 by
activated intraislet macrophages in rodent and human islets
leads to b-cell dysfunction and damage [13,14,62].
In this report we have evaluated the cellular mechanisms by
which the macrophage-derived cytokine IL-1 kills b-cells.
Using three different methods to evaluate cell viability, MTT
oxidation, neutral red uptake, and TUNEL staining (DNA
damage), we show that IL-1 induces b-cell death (see Figures
1 3). Nitric oxide appears to be one mediator of b-cell death,
as NOS inhibition attenuated cell death in response to IL-1,
and nitric oxide, supplied exogenously using donor com-
pounds, reduced b-cell viability. The mechanism by which IL-
1s t i m u l a t e sb-cell death is both morphologically and
biochemically different from known inducers of apoptosis.
Morphologically, IL-1-induced b-cell death is characterized
by cell swelling and diffuse TUNEL staining—changes
indicative of the loss of membrane integrity, or necrosis. In
response to inducers of apoptosis, the morphology of dying
b-cells differs drastically from the effects of IL-1. Apoptosis
induction results in cell shrinkage and tight, punctate TUNEL
staining, consistent with the form of cell death that we have
observed with known inducers of apoptosis. To investigate
biochemical mechanisms responsible for b-cell death, we
evaluated the effects of IL-1 on caspase-3 activation and PS
externalization (annexin staining). Caspase-3 activity was
chosen because it the executioner caspase activated by
initiator caspases involved in both extrinsic and intrinsic
apoptotic pathways [39,40]. While many reports have sug-
gested that IL-1 induces b-cell death by apoptosis, we show
that IL-1 fails to activate caspase-3 or to stimulate annexin V
staining in islets or RINm5F cells. In contrast, known
apoptosis inducers stimulated 6- to 9-fold increases in
caspase-3 activity and signiﬁcantly increased annexin V
staining on RINm5F cells and rat islet cells. The lack of
RINm5F cell and islet caspase activity following treatment
with IL-1 is not surprising, as IL-1 stimulates b-cell
production of nitric oxide, and nitric oxide has been shown
to inhibit caspase activity by S-nitrosation of the active site
cysteine [41,43].
Since these ﬁndings suggest that the macrophage-derived
cytokine IL-1 does not induce apoptosis, we sought to identify
whether IL-1 kills b-cells by necrosis. The morphological
changes (see Figure 3) and the diffuse TUNEL staining in
RINm5F cells and rat islet cells (see Figures 4 and 5) induced
by IL-1 treatment are consistent with a necrotic type of cell
death. To provide biochemical evidence in support of IL-1-
induced b-cell necrosis, the effects of this cytokine on the
release of HMGB1 from b-cells was examined. HMGB1 is a
chromatin-binding protein that functions to distort the
double helix, allowing proper physical interactions between
transcription factors and chromatin [63]. Recent studies have
shown that HMGB1 is released from cells dying by necrosis,
but it remains tightly bound to chromatin in cells undergoing
apoptosis [26,44–46]. In this study, we show that IL-1
stimulates HMGB1 release from RINm5F cells and rat islets
in a nitric oxide-dependent manner, and that HMGB1 release
is not affected by the inhibition of caspase activity. These
ﬁndings suggest that IL-1-induced HMGB1 release is medi-
ated, at least in part, by nitric oxide, a conclusion further
supported by the ability of nitric oxide to directly stimulate
HMGB1 release by RINm5F cells and rat islets. Importantly,
under conditions in which RINm5F cells or islets have been
forced to undergo apoptosis, HMGB1 was not released.
Overall, this morphological and biochemical evidence sup-
ports b-cell necrosis as the primary mechanism by which IL-1
induces b-cell death, and that this death pathway is mediated,
in part, by nitric oxide.
While IL-1 is sufﬁcient to inhibit the function and to
induce the death of rat b-cells, alone, the exogenous
addition of IL-1 does not inhibit the function or induce
death of human b-cells [47,48]. A combination of the
cytokines IL-1, TNF, and IFN-c is required to impair human
b-cell function and induce islet cell death [47,48]. Treatment
of human islets for 24- or 48-h with IL-1 þ IFN-c þ TNF
results in inhibition of glucose-stimulated insulin secretion
and mitochondrial aconitase activity, effects attenuated by
the iNOS inhibitors NMMA and AG [47,64]. In addition, the
local release of IL-1 by intraislet macrophages in response to
TNF þ IFN-c þ LPS treatment results in inhibition of
glucose-stimulated insulin secretion that is attenuated by
inhibitors of iNOS [14]. These ﬁndings support a role for
nitric oxide as a mediator of cytokine-induced b-cell damage
in human following exposures of 24 and 48 h. In contrast,
extended incubation (for 6–9 d) of human islets with IL-1 þ
TNF þ IFN-c has been reported to inhibit insulin secretion
and induce b-cell apoptosis in a nitric oxide-independent
manner [19,48]. The latter ﬁndings have led to speculation
that human islets are less sensitive to nitric oxide than are
rodent islets [65]. Comparisons of cellular responses to
cytokines across species are complicated by the genetic
background of each species. This is especially true when
using human islets in which the genetic background is
different for each individual human islet preparation. In
contrast, studies with rodent islets are usually performed
with a speciﬁc strain of rat or mouse. Importantly, Nerup
and coworkers have shown that the ability of IL-1 to inhibit
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three different rat strains [66]. These ﬁndings suggest that
the genetic background, even within a given species of
animal, contributes to the islet response to cytokines. Taking
this into account, we have evaluated the effects of IL-1, TNF,
and IFN-c on nitric oxide production and HMGB1 release
by human islets. In three of ﬁve preparations, the
combination of cytokines stimulated HMGB1 release by
human islets by a mechanism that was sensitive to inhibition
by the iNOS inhibitors AG (Figure 10) and NMMA
(unpublished data). Importantly, in two human islet prepa-
rations the combination of cytokines failed to stimulate
HMGB1 release and also failed to stimulate nitric oxide
production or iNOS expression. The reason for this lack of
response to cytokines in two of the human islet preparations
is unknown; however, it has been reported that elevated
levels of heat-shock protein 70 attenuate the ability of b-cells
to express iNOS and produce nitric oxide, and the strain
differences in response of rat islets to IL-1 have been
reported to be associated with differences in levels of heat-
shock protein 70 expression [67–69]. Taking this into
account, our ﬁndings suggest that when human islets
produce sufﬁcient levels of nitric oxide in response to
cytokines, one consequence is the release of HMGB1. In
contrast, when human islets fail to respond to cytokines by
producing nitric oxide, they also do not release HMGB1.
HMGB1 is not only a marker of cells undergoing necrosis,
but it is also immunologically active. It has been shown to
bind to Toll2 and Toll4 receptors and to activate nuclear
factor jB-dependent gene expression [70–72], and antago-
nists of HMGB1 have been shown to attenuate sepsis in
animal models [73]. It is well established that necrotic cells
release immunological adjuvants that activate APCs and that
amplify and sustain T cell-dependent immune responses
[74–76]. Recently, Rovere-Querini et al. showed that necrotic
HMGB1-deﬁcient cells have a reduced capacity to activate
APCs, and that HMGB1 neutralization attenuates the ability
of supernatants derived from necrotic wild-type cells to
activate APCs [77]. HMGB1 also appears to enhance primary
antibody responses to soluble antigens and to enhance
cytotoxic lymphocyte responses [77]. While caution should
be exercised when extrapolating in vitro ﬁndings to
mechanisms of disease pathogenesis, it is tempting to
speculate on the potential role of intraislet macrophage
activation as a precipitating event in the development of
autoimmune diabetes. In previous studies, we have shown
that the 10–15 resident macrophages found in islets, when
activated, produce IL-1 to levels sufﬁcient to inhibit b-cell
function in a manner similar to that occurring with the
exogenous addition of this cytokine to islets [13,14,78]. We
now show that, at these same concentrations, IL-1 kills b-
cells by necrotic mechanisms that are associated with the
release of the immunological adjuvant HMGB1—a molecule
known to augment APC activation and cytolytic responses of
T cells.
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Background. Type 1 diabetes (also called autoimmune diabetes or
juvenile diabetes) is an autoimmune disease. For unknown reasons, at
some point in childhood or adolescence, the body’s own immune system
starts attacking and destroying the insulin-producing islet cells in the
pancreas. Once the majority of islet cells are destroyed, patients can no
longer produce insulin to regulate their blood sugar and must depend
on strict diets and insulin injections. Scientists are trying to understand
the early events during the development of the disease. There are two
fundamentally different kinds of cell death in cells of higher animals and
humans, called apoptosis and necrosis. Apoptosis (also called pro-
grammed cell death) is an organized, clean way in which cells die
without spilling their contents and without causing an inflammatory
immune response. They are simply gobbled up by other cells that serve
as the body’s garbage collectors. Necrosis, on the other hand, is a more
messy process and one that does activate the immune system and cause
local inflammation.
Why Was This Study Done? The scientists who did this study are
interested in the early stages of islet cell death. Specifically, they wanted
to know whether islet cells during the early events of autoimmune
diabetes die via apoptosis or necrosis. Earlier experiments to address this
question had yielded no clear-cut results.
What Did the Researchers Do and Find? All the experiments for this
study were done in cultured cells in the laboratory. For the most part, the
researchers used rodent islet cells, and then they confirmed the crucial
finding in human islet cells. They grew the cells under conditions that
resembled, to the best of their knowledge, the early stages of diabetes,
which caused some of the cells to die. They then did a variety of tests to
see whether that cell death was through apoptosis or necrosis, and the
results showed that the latter was the case. They also identified some of
the key factors involved in promoting and executing the necrosis
process.
What Does This Mean? One must always be careful to extrapolate from
laboratory results like these. With this caveat, the results suggest that
early in the development of diabetes cells die by necrosis, and they point
to some of the key factors involved. These are important results that will
inform future studies toward the goal of understanding autoimmune
diabetes well enough to prevent or stop its development.
Where Can I Find More Information Online? The following Web sites
provide information on autoimmune diabetes.
MedlinePlus pages on type 1 diabetes:
http://www.nlm.nih.gov/medlineplus/ency/article/000305.htm
Web site of the Juvenile Diabetes Research Foundation:
http://www.jdrf.org/index.cfm?page_id¼101982
Pages on type 1 diabetes from the Canadian Diabetes Association:
http://www.diabetes.ca/Section_About/type1.asp
Type 1 diabetes pages from the UK National Institute for Health and
Clinical Excellence:
http://www.nice.org.uk/page.aspx?o¼213575
UK National Diabetes Information Clearinghouse:
http://diabetes.niddk.nih.gov/index.htm
American Diabetes Association Web site:
http://www.diabetes.org
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